research use only

Paricalcitol Vitamin agonist

Cat.No.S6681

Paricalcitol is a selective vitamin D receptor agonist. This compound suppresses parathyroid hormone mRNA expression and inhibits parathyroid cell proliferation. It is used to treat secondary hyperparathyroidism in chronic kidney disease.
Paricalcitol Vitamin agonist Chemical Structure

Chemical Structure

Molecular Weight: 416.64

Quality Control

Batch: S668101 DMSO]83 mg/mL]false]Ethanol]13 mg/mL]false]Water]Insoluble]false Purity: 99.99%
99.99

Chemical Information, Storage & Stability

Molecular Weight 416.64 Formula

C27H44O3

 

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 131918-61-1 -- Storage of Stock Solutions

Synonyms Paracalcin,19-Nor-1-25-OH2D2,19-Nor-colecalciferol Smiles CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C

Solubility

In vitro
Batch:

DMSO : 83 mg/mL ( (199.21 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 13 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
vitamin D receptor [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05664880 Recruiting
Chronic Pancreatitis
Cedars-Sinai Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
June 1 2023 Early Phase 1
NCT03415854 Completed
Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma|Pancreatic Adenocarcinoma|Pancreas Metastases|Adenocarcinoma
HonorHealth Research Institute|Barts Cancer Institute|Abramson Cancer Center at Penn Medicine|Salk Institute for Biological Studies|Mayo Clinic|Princeton University|Imaging Endpoints|Translational Genomics Research Institute|Stand Up To Cancer|Cancer Research UK|Lustgarten Foundation|University of California San Diego
January 31 2018 Phase 2
NCT03331562 Completed
Pancreatic Cancer|Pancreas Adenocarcinoma|Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma
Translational Genomics Research Institute|Stand Up To Cancer|Merck Sharp & Dohme LLC
December 27 2017 Phase 2
NCT02686827 Completed
Hypersensitivity
Laurian Jongejan|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
October 2015 Phase 2
NCT01725113 Terminated
Kidney Failure|Secondary Hyperparathyroidism|Hyperphosphatemia|Hypercalcemia
Winthrop University Hospital
November 2012 Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.